JPWO2022125598A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022125598A5 JPWO2022125598A5 JP2023534386A JP2023534386A JPWO2022125598A5 JP WO2022125598 A5 JPWO2022125598 A5 JP WO2022125598A5 JP 2023534386 A JP2023534386 A JP 2023534386A JP 2023534386 A JP2023534386 A JP 2023534386A JP WO2022125598 A5 JPWO2022125598 A5 JP WO2022125598A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- week
- human
- body weight
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122117P | 2020-12-07 | 2020-12-07 | |
| US63/122,117 | 2020-12-07 | ||
| US202163211157P | 2021-06-16 | 2021-06-16 | |
| US63/211,157 | 2021-06-16 | ||
| US202163249468P | 2021-09-28 | 2021-09-28 | |
| US63/249,468 | 2021-09-28 | ||
| PCT/US2021/062286 WO2022125598A1 (en) | 2020-12-07 | 2021-12-07 | Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500324A JP2024500324A (ja) | 2024-01-09 |
| JPWO2022125598A5 true JPWO2022125598A5 (enrdf_load_stackoverflow) | 2024-11-20 |
Family
ID=81972768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534386A Pending JP2024500324A (ja) | 2020-12-07 | 2021-12-07 | Ｇｌｐ－１ｒおよびｇｃｇｒ均衡アゴニストを使用した血糖および／または体重を低下させるための治療レジメンおよび方法 |
Country Status (8)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4587045A2 (en) * | 2022-09-14 | 2025-07-23 | Spitfire Pharma LLC | Therapeutic regimens and methods for reducing body weight in a subject with fatty liver disease using a glp-1r and gcgr agonist |
| WO2024098071A1 (en) * | 2022-11-05 | 2024-05-10 | Spitfire Pharma Llc | Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist |
| CN118477048B (zh) * | 2024-05-24 | 2024-12-17 | 山东泰合医药科技有限公司 | 一种布瑞哌唑缓释微球及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2708762A1 (en) * | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
| AU2015266854B2 (en) * | 2014-05-28 | 2020-03-26 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| MY191321A (en) * | 2016-03-10 | 2022-06-15 | Medimmune Ltd | Glucagon and glp-1 co-agonists for the treatment of obesity |
| MX2020006999A (es) * | 2018-01-03 | 2020-12-10 | Mederis Diabetes Llc | Farmaceuticos de peptidos mejorados para el tratamiento de nash y otros trastornos. |
| US20200262887A1 (en) * | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
-
2021
- 2021-12-07 MX MX2023006736A patent/MX2023006736A/es unknown
- 2021-12-07 JP JP2023534386A patent/JP2024500324A/ja active Pending
- 2021-12-07 CA CA3201539A patent/CA3201539A1/en active Pending
- 2021-12-07 EP EP21904289.2A patent/EP4255564A4/en active Pending
- 2021-12-07 WO PCT/US2021/062286 patent/WO2022125598A1/en active Application Filing
- 2021-12-07 KR KR1020237022812A patent/KR20230129425A/ko active Pending
- 2021-12-07 IL IL303512A patent/IL303512A/en unknown
-
2024
- 2024-11-11 US US18/943,449 patent/US20250134963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112007023A (zh) | 黄芩素在制备防治肥胖症及其并发症药物中的用途 | |
| US20230092769A1 (en) | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs | |
| JP7639156B2 (ja) | チルゼパチド治療方法 | |
| WO2005016370A1 (en) | Method of treating viral infections | |
| JPWO2022125598A5 (enrdf_load_stackoverflow) | ||
| Reznik | Continuous subcutaneous insulin infusion (CSII) using an external insulin pump for the treatment of type 2 diabetes | |
| JP5034944B2 (ja) | インターフェロン作用物質の活性増強剤 | |
| BR112020018362A2 (pt) | Composição de glp-1 para tratar obesidade e controle de peso | |
| WO2023231730A2 (zh) | 使用mazdutide的治疗方法 | |
| CN110433160A (zh) | 一种治疗肝纤维化的化合物及其应用 | |
| JP2021169472A5 (enrdf_load_stackoverflow) | ||
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| CN113876907A (zh) | 四味姜黄汤散在防治糖尿病周围神经病变中的应用 | |
| RU2834226C2 (ru) | Композиция glp-1 для лечения ожирения и регулирования веса | |
| EP3804705A1 (en) | Pharmaceutical composition for preventing diabetes and use thereof | |
| US20230081034A1 (en) | Dosing regimen of glp-1 | |
| US20060166957A1 (en) | Methods of treating obesity and related disorders using tellurium selenium compounds | |
| US11452754B2 (en) | Pharmaceutical composition and uses thereof | |
| CN110575447B (zh) | 一种用于防治糖尿病的药物组合物及其用途 | |
| JPWO2021202825A5 (enrdf_load_stackoverflow) | ||
| JPH06234642A (ja) | 有機化合物に関する改良 | |
| HK40083623A (en) | Dosing regimen of glp-1 | |
| CN120168610A (zh) | 一种白细胞介素-13在促进肌肉损伤后修复中的应用 | |
| CN116712420A (zh) | 一种花椒酰胺在制备治疗多发性硬化症的药物中的应用 | |
| WO2024042518A1 (en) | Glp-1 receptor antagonist and methods of use thereof |